King's College London, Guy's & St Thomas' Hospital, Department of Critical Care, London, England.
Divisions of Nephrology and Critical Care Medicine, Departments of Medicine and Anesthesia, University of California San Francisco, San Francisco, CA.
Chest. 2019 Sep;156(3):594-603. doi: 10.1016/j.chest.2019.04.004. Epub 2019 Apr 16.
Correction of intravascular hypovolemia is a key component of the prevention and management of acute kidney injury (AKI), but excessive fluid administration is associated with poor outcomes, including the development and progression of AKI. There is growing evidence that fluid administration should be individualized and take into account patient characteristics, nature of the acute illness and trajectories, and risks and benefits of fluids. Existing data support the preferential use of buffered solutions for fluid resuscitation of patients at risk of AKI who do not have hypochloremia. There is a limited role for albumin, and starches should be avoided. Fluids should only be administered until intravascular hypovolemia has been corrected and euvolemia has been achieved using the minimum amount of fluid required to achieve and maintain euvolemia. Oliguria alone should not be viewed as a trigger for fluid administration. If fluid overload occurs, fluid therapy needs to be discontinued, and fluid removal using diuretic agents or extracorporeal therapies should be considered.
纠正血管内血容量不足是预防和治疗急性肾损伤(AKI)的关键环节,但过度输液与不良结局相关,包括 AKI 的发生和进展。越来越多的证据表明,输液应个体化,并考虑患者的特点、急性疾病的性质和轨迹,以及液体的风险和益处。现有数据支持在无低氯血症的 AKI 风险患者中,优先使用缓冲溶液进行液体复苏。白蛋白的作用有限,应避免使用淀粉类药物。只有在纠正血管内血容量不足并达到并维持正常血容量所需的最少液体量时,才可输注液体。单纯少尿不应作为输液的触发因素。如果发生液体超负荷,应停止输液,并考虑使用利尿剂或体外治疗来清除液体。